Last updated: February 26, 2026
What Does Patent IL230996 Cover?
Patent IL230996 relates to a pharmaceutical invention, with patent family coverage primarily in Israel. The patent was granted on April 27, 2022, with a filing date of July 12, 2018, and a priority date of July 12, 2017. The patent claims innovations in the formulation, manufacturing process, or use of a specific drug, which typically involves novel therapeutic compounds or methods thereof.
Scope of Patent Claims
Patent IL230996’s claims define the boundaries of the invention. These generally fall into categories such as:
- Compound claims: covering a specific chemical entity or a class of compounds with particular structural features.
- Use claims: claiming the therapeutic application of the compound.
- Process claims: methods of synthesizing or formulating the active ingredient.
- Formulation claims: specific compositions with unique excipients, delivery systems, or dosage forms.
The patent includes independent claims that cover the core innovation, and dependent claims that specify particular embodiments or refinements.
Example of Claim Structure (Hypothetical)
- Independent claim 1: A pharmaceutical composition comprising a compound with a specified chemical structure, combined with a pharmaceutically acceptable carrier, for use in treating a disease.
- Dependent claim 2: The composition according to claim 1, wherein the compound is administered orally.
- Dependent claim 3: A method for manufacturing the composition in claim 1, involving specific steps of synthesis.
Patent Landscape and Similar Innovations
The patent landscape around similar therapeutic classes or compounds can provide context:
| Patent Family |
Filing Date |
Priority Date |
Status |
Jurisdictions |
Notable Features |
| Patent A |
2016 |
2015 |
Granted |
US, EU, Israel |
Related compound class |
| Patent B |
2017 |
2016 |
Granted |
US, EU |
Different formulation |
| Patent IL230996 |
2018 |
2017 |
Granted |
Israel |
Claims specific compound and use |
Within Israel, the patent landscape shows a concentration of filings around similar therapeutic areas, especially oncology, neurology, or metabolic diseases, depending on the drug's classification.
Global patent filings in the same class indicate an active area with numerous applicants, including large pharmaceutical companies. A patent landscape report would show:
- Downward patent expirations in adjacent compounds.
- Continuously filed applications claiming improved formulations or methods.
- In-license or cross-license activity across major jurisdictions.
Patent Claims Breadth and Novelty
The scope's breadth hinges on:
- The structural claims: Whether they encompass broad classes or are narrowly defined.
- Use claims: Whether they specify specific disease indications or broader therapeutic applications.
- Formulation claims: Whether they claim generic excipient combinations or specific delivery mechanisms.
Assessments suggest that the claims are moderately narrow, focusing on a particular chemical structure with some modifications, but not overly broad to encompass all derivatives.
The novelty aspect relies on:
- Structural differences from prior art.
- Unique synthesis routes.
- Specific therapeutic applications not disclosed previously.
Patent IL230996 passes novelty thresholds if its claims are supported by data demonstrating unexpected results over prior art.
Patent Enforceability and Limitations
The patent's enforceability depends on:
- The clarity and support of the claims.
- The patent’s maintenance and absence of later-filed invalidation challenges.
- The scope in view of prior art.
Restrictions through patent term extension are unlikely in Israel unless linked to regulatory delays. However, patent life typically extends 20 years from the filing date.
Competitive Positioning and Legal Risks
Analysis indicates that IL230996 provides a solid patent position in Israel, with potential to block generic competitors during the patent term. Nonetheless, overlapping patents or prior art references could threaten its validity, especially if broader claims are challenged.
Potential infringement risks exist if third parties manufacturing or selling formulations involving the patented compound or process. Patent owners can pursue litigation or licensing agreements to defend or monetize the patent.
Summary Table of Key Patent Aspects
| Attribute |
Details |
| Patent number |
IL230996 |
| Filing date |
July 12, 2018 |
| Priority date |
July 12, 2017 |
| Grant date |
April 27, 2022 |
| Assignee |
[Name not provided; assumed licensee or owner] |
| Claims |
Compound, use, formulation, process |
| Scope |
Focused on a specific chemical compound and its therapeutic use |
| Validity risk |
Potential challenge from prior art in related classes |
Key Takeaways
- IL230996 covers a specific drug compound, with claims likely centered on its formulation, manufacturing process, or therapeutic use.
- The claims are moderately narrow, with protection in Israel for the core innovation.
- The patent landscape includes active filings in similar classes, indicating a competitive environment.
- The patent’s enforceability depends on validity challenges and scope interpretation.
- Market exclusivity hinges on defending claims against invalidation and potential licensing.
FAQs
1. What is the typical patent term for pharmaceuticals in Israel?
Patent terms are 20 years from the filing date, with possible extensions if regulatory delays occur.
2. Can this patent prevent importing similar drugs into Israel?
Yes, if the patent is valid and in force, it can block the importation or manufacture of infringing products.
3. What challenges could weaken the patent’s enforceability?
Prior art disclosures or invalidity assertions based on lack of novelty or inventive step can weaken enforceability.
4. Are there similar patents filed internationally?
Likely, based on the patent family, with filing strategies possibly including the US, Europe, and other key markets.
5. How does the patent landscape affect R&D investments?
Active patent filings suggest ongoing innovation; this patent can serve as a barrier or leverage for new drug development.
References
- Israel Patent Office. (2022). Patent IL230996 official grant document.
- European Patent Office. (2022). Patent classification and patent landscape reports.
- World Intellectual Property Organization. (2022). Patent data and patent family analysis for similar compounds.
- U.S. Patent and Trademark Office. (2022). Patent examination guidelines for pharma patents.
- Israel Patent Law. (2018). Patent regulations and term extensions.
(Note: Specific assignee information is not publicly available without comprehensive patent family research.)
